Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 360, Issue 3, 1999, Pages 256-261

  Ferger, Boris ^a   Teismann, Peter ^a   Earl, Christopher D ^a   Kuschinsky, Klaus ^a   Oertel, Wolfgang H ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Hydroxyl radicals; Neuroprotection; Parkinson's disease; Radical scavenger; Salicylic acid

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2,3 DIHYDROXYBENZOIC ACID; 3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; GENTISIC ACID; HOMOVANILLIC ACID; SALICYLATE SODIUM; SCAVENGER; SODIUM CHLORIDE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATECHOLAMINE DEPLETION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PERIKARYON; SUBCUTANEOUS DRUG ADMINISTRATION; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL COUNT; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FREE RADICAL SCAVENGERS; HOMOVANILLIC ACID; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; NEOSTRIATUM; NEURONS; PARKINSON DISEASE, SECONDARY; PROTECTIVE AGENTS; SALICYLATES; SUBSTANTIA NIGRA; SYNAPTIC TRANSMISSION; TYROSINE 3-MONOOXYGENASE;

EID: 0032862588     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002109900079     Document Type: Article

References (36)

1. Aubin N, Curet O, Deffois A, Carter C (1998) Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 71:1635-1642
2. Beal MF (1995) Aging, energy and oxidative stress in neurodegenerative diseases. Ann Neurol 38:357-360
3. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415-155
4. Czlonkowska A, Kohutnicka M, Kurkowska-Jastrzebska I, Czlonkowski A (1996) Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 5:137-143
5. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52:1830-1836
6. Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten hei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 38:1236-1239
7. Fahn S (1997) Levodopa-induced neurotoxicity. CNS Drugs 8:376-393
8. Ferger B, Amsterdam C van, Seyfried C, Kuschinsky K (1998a) Effects of α-phenyl-tert-butylnitrone and selegiline on hydroxyl free radicals in rat striatum produced by local application of glutamate. J Neurochem 70:276-280
9. Ferger B, Teismann P, Themann C, Kuschinsky K (1998b) Determination of 6-hydroxydopamine-induced hydroxyl free radical stimulation: an in vivo microdialysis study. Soc Neurosci Abstr 24:1469
10. Ferger B, Spratt C, Teismann P, Seitz G, Kuschinsky K (1998c) Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo. Eur J Pharmacol 360:155-163
11. Floyd RA, Watson JJ, Wong PK (1984) Sensitive assay of hydroxyl free radical formation utilizing high pressure liquid chromatography with electrochemical detection of phenol and salicylate products. J Biochem Biophys Methods 10:221-235
12. Gerlach M, Riederer P (1996) Animal models of Parkinson's disease: an empirical comparison with phenomenology of the disease in man. J Neural Transm 103:987-1041
13. Gerlach M, Riederer P, Przuntek H, Youdim MBH (1991) MPTP mechanism of neurotoxicity and their implication for Parkinson's disease. Eur J Pharmacol 208:279-286
14. Grilli M, Pizzi M, Memo M, Spano P (1996) Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science 274:1383-1385
15. Ingelman-Sundberg M, Kaur H, Terelius Y, Person J-O, Halliwell B (1991) Hydroxylation of salicylate by microsomal fractions and cytochrome P-450. Biochem J 276:753-757
16. Insel P (1996) Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A (eds) Goodman and Gilman's the pharmacological basis of therapeutics, 9th edn. McGraw-Hill, New York, pp 617-657
17. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S (1995) Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4:257-269
18. Jenner P (1998) Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 13 [Suppl 1]:24-34
19. Kaur H, Whiteman M, Halliwell B (1997) Peroxynitrile-dependent hydroxylation and nitration of salicylate and phenylalanine. Is hydroxyl radical involved? Free Radic Res 26:71-82
20. Kupsch A, Gerlach M, Pupeter SC, Sautter J, Dirr A, Arnold G, Opitz, W, Przuntck H, Riederer P, Oertel WH (1995) Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. Neuroreport 6:621-625
21. Kuschinsky K, Ferger B (1996) A sensitive HPLC method for measuring highly-reactive hydroxyl radicals in vitro and in vivo. Naunyn-Schmiedeberg's Arch Pharmacol 353:R100
22. Langston JW, Ballard PA, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of mepiridine-analog synthesis. Science 219:979-980
23. Lehmann A (1974) Atlas stéréotaxigue du cerveau de la souris. Editiones du Centre National de Recherche Scientifique, Paris
24. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer disease brains. Neurology 38:1285-1291
25. Mitchell JA, Saunders M, Barnes PJ, Newton R, Belvisi MG (1997) Sodium salicylate inhibits cyclo-oxygenase-2 activity independently from transcription factor (nuclear factor kappaB) activation: role of arachidonic acid. Mol Pharmacol 51: 907-912
26. Patrono C (1994) Aspirin as an antiplatelet drug. N Engl J Med 330:1287-1294
27. Przedborski S, Jackson-Lewis V (1998) Mechanisms of MPTP toxicity. Mov Disord 13 [Suppl 1]:35-38
28. Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL, Dawson TM (1996) Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA 93: 4565-4571
29. Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 38: 277-301
30. Rossetti ZL, Sotgiu A, Sharp DE, Hadjiconstantinou M, Neff NH (1988) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro. Biochem Pharmacol 37:4573-4574
31. Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex 1 deficiency in Parkinson's disease. J Neurochem 54:823-827
32. Schulz JB, Matthews RT, Jenkins BG, Ferrante RJ, Siwek D, Henshaw DR, Cippolloni PB, Mecocci P, Kowall NW, Rosen BR, Beal MF (1995) Blockade of neuronal nitric oxide synthase protects against excitotoxicily in vivo. J Neurosci 15:8419-8429
33. Smith TS, Bennett JP Jr (1997) Mitochondrial toxins in models of neurodegenerative diseases. I. In vivo brain hydroxyl radical production during systemic MPTP treatment or following microdialysis infusion of methylpyridinium or azide ions. Brain Res 765:183-188
34. Smith TS, Swerdlow RH, Parker WD Jr, Bennett JP Jr (1994) Reduction of MPP(+) induced hydroxyl radical formation and nigrostriatal MPTP toxicity by inhibiting nitric oxide synthase. Neuroreport 5:2598-2600
35. Tipton KF, Singer TP (1993) Advances in our understanding of the mechanism of the neurotoxicity of MPTP and related compounds. J Neurochem 61:1191-1206
36. Yin M-J, Yamamoto Y, Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 396:77-80